BioStock Studio: Scandion Oncology and Alligator Bioscience forge preclinical collaboration
Yesterday, Nils Brünner, CEO of the Danish Scandion Oncology and Per Norlén, CEO of Swedish Alligator Bioscience came together at the BioStock Studio to discuss their newly forged collaboration. The two companies have recently agreed to explore the anti-tumour effect of Alligator’s mitazalimab in combination with Scandion’s SCO-101 as an addition to chemotherapy in resistant preclinical tumour models. The two CEOs expect that SCO-101 will be able to revert chemotherapy resistance and thereby further strengthen the anti-tumour effects of mitazalimab.
Watch the video interview with Scandion Oncology's CEO Nils Brünner and Alligator Bioscience's CEO Per Norlén at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se